IlluminaRachel E. Sanborn, MD, presents the journey of a patient diagnosed with atypical carcinoid with brain metastases who benefited from the detection of a RET fusion by comprehensive genomic profiling.
Rachel E. Sanborn, MD is the medical director of the Thoracic Oncology and Phase I Clinical Trials Programs at the Earle A. Chiles Research Institute at Providence Cancer Institute.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Illumina Oncology - Does finding a rare mutation accomplish anything?Illumina2024-01-10 | Rachel E. Sanborn, MD, presents the journey of a patient diagnosed with atypical carcinoid with brain metastases who benefited from the detection of a RET fusion by comprehensive genomic profiling.
Rachel E. Sanborn, MD is the medical director of the Thoracic Oncology and Phase I Clinical Trials Programs at the Earle A. Chiles Research Institute at Providence Cancer Institute.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaIllumina Public Health Education Scholarship Awards Ceremony 2024Illumina2024-04-30 | Illumina and the Chinese National Health Commission’s International Health Exchange and Cooperation Center (IHECC) launched the Illumina Public Health Education Scholarship program. The scholarship program’s award ceremony for the 2022–23 academic year was held on March 26, 2024, at Peking University Health Science Center. Since the launch of the program in 2022, nearly 300 students from five universities have received scholarships.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#STEM #chinapublichealtheducation #illuminaImpact in Action | Meet our EmployeesIllumina2024-04-29 | What's it like to work at Illumina? Innovative, connected, impactful – take it from our employees.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#IlluminaCareers #IlluminaProud #Genomics #illuminaThe Future is Bright: Career exploration through hands-on experiences in the classroomIllumina2024-04-29 | Meghan, an 11th grade biology teacher, shares her passion for immersive hands-on learning, genomics-centered curriculum and career exploration into her San Diego classroom! Celebrate The Future is Bright and watch this video to learn how Megan inspires her students to explore careers and industries. Share your classroom and experiments using #Genomics4All
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#IlluminaCares #Genomics4all #STEMHRH The Princess Royal Helps Illumina Mark DNA DayIllumina2024-04-26 | This year's DNA Day festivities at the Illumina Centre in Granta Park, Cambridge, saw the participation of 150 enthusiastic children from local Cambridgeshire schools in underserved areas. They were joined by HRH The Princess Royal. The young learners engaged in hands-on experiences, including the thrilling task of extracting DNA from strawberries. In addition to the educational activities, the students were treated to a tour of one of Illumina's state-of-the-art laboratories. This behind-the-scenes glimpse into the world of genomic research offered valuable insights and inspiration to young scientists, notably highlighting the importance of women in the field. This experience not only provided an insight into the world of genomics, but it also may inspire many to one day play a pioneering role in research and innovation at companies such as Illumina.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#illumina #DNAday #STEMConnect Your AWS S3 Bucket to an Illumina® Connected Analytics ProjectIllumina2024-04-17 | In this video, we demonstrate how to connect your own AWS S3 bucket as a storage configuration for your Illumina® Connected Analytics (ICA) project.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#ICA #AWS #illuminaIllumina PRS grant winner investigates genetic linkage between opioid use disorder and chronic painIllumina2024-04-11 | Illumina congratulates Emma Johnson, PhD, Assistant Professor in Psychiatry at Washington University School of Medicine in St. Louis for winning the Illumina Polygenic Research Grant Contest. Professor Johnson and her colleagues, Arpana Agrawal, PhD, Professor of Psychiatry, and Simon Haroutounian, PhD, Chief of Clinical Research at the Washington University Pain Center, will use Illumina and Allelica technology to genotype at least 1000 surgery patients from an ongoing P5 study (PI: Dr. Haroutounian) to understand the transition from acute to chronic postoperative pain. Ultimately, this research aims to develop polygenic risk scores (PRS) for chronic pain and Opioid Use Disorder (OUD), enabling clinicians to one day more effectively manage and prevent post-surgical pain, as well as providing a resource for stratification of high-risk individuals who may develop OUD alongside chronic pain.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaNextSeq™ 2000 at The SGS Global Biosciences Center - LisbonIllumina2024-04-05 | Vanessa Luís and João Rodrigues from the Global Biosciences Center, part of SGS in Lisbon share their experience of the NextSeq™ 2000, from extending their capabilities beyond amplicon sequencing to increasing capacity and identifying rare species through environmental monitoring, find out more about their experiences in this video.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaInfinium Arrays: With Infinium and BeyondIllumina2024-04-01 | Infinium arrays are a powerful tool for analyzing genetic variation across the genome. They are a robust technology capable of generating comprehensive coverage of genetic variants, high-throughput genotyping whilst remaining cost-effective, and scalable. These features have led to Infinium arrays to be the technology of choice in applications such as genome-wide association studies (GWAS), that investigate the genetic basis of complex diseases and traits, and population genetics studies. Data generated by arrays can also be integrated with other types of genetic data, such as gene expression profiles or methylation data providing deeper insights into an individual's genetic make-up. Infinium arrays are a complementary technology to next-generation sequencing (NGS).
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Optimized for Illumina sequencing platforms, each kit provides highly reproducible results across sample types and experiments—even from the most challenging samples.
Discover the ease of adoption with superior support across the entire workflow.
Learn more about library prep products for: • Whole Genome Sequencing • Whole Transcriptome Sequencing • Target DNA Sequencing • Target RNA Sequencing
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaEarlham Institute and WorldFish: Changing the World with NovaSeq™ X PlusIllumina2024-03-25 | Feeding the world’s growing population requires big advances in sustainable aquaculture, and in this video, three scientists describe how the Illumina NovaSeq X Series is helping make those advances possible.
John Benzie, acting director of Aquatic Foods Biosciences at WorldFish, explains how his organization develops strains of tilapia that grow faster and can better tolerate climate change and disease.
They make these breeding decisions equipped with sequencing data from the Earlham Institute, where Karim Gharbi, head of Genomics Pipelines, and Tarang Mehta, postdoctoral researcher use multomics to identify genetic markers in tilapia DNA that express these desirable traits—all in the interest of translating the work they do at the genomic level directly into sustaining food biodiversity.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
0:00 – A fish population in decline 0:50 – John Benzie and WorldFish’s mission 1:24 – The importance of aquaculture to food security 2:03 – Sampling for Earlham Institute 2:36 – Tarang Mehta and genomic sequencing of Tilapia 3:03 – Karim Gharbi and collaboration with WorldFish 3:37 – Working with the NovaSeq™ X Plus 4:15 – A combined passion for technology and sustainable food productionHow Tuberculosis (TB) experts are using Next-Generation Sequencing in their fight against DR-TBIllumina2024-03-25 | Drug-resistant tuberculosis (DR-TB) poses a major threat, but next-generation sequencing (NGS) offers a powerful solution. In this video, leading tuberculosis (TB) experts discuss how Next-Generation Sequencing (NGS) is transforming surveillance, research, diagnostics, and ultimately, patient outcomes.
Featured experts: • Prof. Dr. Stefan Niemann, Research Center Borstel Leibniz Lung Center, Germany • Dr. Ameeta Joshi, Grant Medical College, India • Dr. Melanie Grobbelaar, Stellenbosch University, South Africa • Dr. Philip Supply, Senior Scientist and Research Director, French National Center for Scientific Research (CNRS) and Institute Pasteur De Lille, France • Ms. Anita Suresh, Deputy Director, Head of Genomics and Sequencing Unit, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland • Dr. Saurabh Rane, Antimicrobial Resistance Fighter Coalition, India
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaDo more with P4 on NextSeq™ 2000Illumina2024-03-18 | Unlock expansive application breadth and enhanced performance on the NextSeq™ 2000 System – now powered by XLEAP-SBS™ chemistry. The new P4 flow cell features 4 new kit configurations, giving you the flexibility to do more, for less.
Access more reads, higher quality, and lower cost – all on the market-leading benchtop system. #NextSeq #XLEAP #Illumina
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A streamlined workflow and broad platform utility with XLEAP-SBS chemistry enables expansive applications on the market-leading benchtop sequencer. #NextSeq #XLEAP #Illumina
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaWhat are the different characteristics of homologous recombination deficiency (HRD) tests?Illumina2024-03-12 | In this video, Dr. Nicola Normanno (National Cancer Institute Pascale Foundation, Naples Italy) explains how the institute became a reference center for NGS and precision oncology in southern Italy. He describes the research on homologous recombination deficiency (HRD) and which assay characteristics labs should consider when internalizing HRD testing for ovarian cancer.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaHomologous recombination deficiency (HRD) and comprehensive genomic profiling (CGP)Illumina2024-03-12 | Dr. Nicola Normanno (National Cancer Institute Pascale Foundation, Naples Italy) explains the clinical need to assess homologous recombination deficiency (HRD) in tumor types beyond ovarian cancer and discusses why comprehensive genomic profiling (CGP) inclusive of HRD is advantageous in identifying actionable mutations with therapeutic interventions. Finally, Dr. Normanno describes the advantages of in-house testing and why he believes it is an exciting time for the Oncology field.
Watch this video to learn more about how CGP and HRD can improve total patient care.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
To perform this step, place the cartridge on a flat surface. Lift the cartridge by the arms approximately 1.5–2.5 in (4–7 cm) above the flat surface as shown, and release onto the bench five times. If cartridge is accidentally dropped, repeat this process. #XLEAP, #NextSeq #Cartridge #howto #Illumina
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Researchers can now explore more with greater depth, precision, and speed, gaining unprecedented insights and propelling progress. LIsten to top scientists around the world share their stories of how NGS technology is advancing their work. Learn more about next-generation sequencing at Illumina.com. #Illumina #cancerresearch #HIVresearch #nextgenerationsequencing
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaVisualize the unknown with RNA-Seq: learn how to start your first RNA-seq projectIllumina2024-03-01 | Every good project starts with a question, and RNA-Seq enables researchers to both address that question and characterize the unknown. Discover how researchers can work with core labs to get expert help with each step of RNA-Seq. Plus, learn the basics about how Illumina NGS works in under 2 minutes.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#illumina #RNASeq #GenomicsFacilities #corelabs #NGSMultiomics Quick Start: Sequencing DNA and RNA from the same sampleIllumina2024-02-21 | Sequencing DNA and RNA from the same sample is the most popular mutliomics approach. In this video, illumina scientists describe best practices for ensuring that sample prep, library prep, and sequencing are high quality so that you're ready for your first multiomics project. For more detailed information about whole genome and transcriptome sequencing, download the quick start guide here: illumina.com/destination/ebook-genomics-transcriptomics.html
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#illumina #multiomics #WholeGenomeSequencing #TranscriptomeSequencing #WGTSIllumina® Connected Analytics: Upload data from local network storage to cloudIllumina2024-02-19 | In this video, we demonstrate how to use the service connector to upload data from your local network storage to the Illumina® Connected Analytics (ICA) platform. This workflow allows you to sequence to cloud without using BaseSpace® Sequence Hub.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#IlluminaConnectedAnalytics #ICA #CloudDataTransfer #CloudStorage #CloudIntegrationIllumina® Connected Analytics: Perform a NovaSeq X run with automated analysisIllumina2024-02-19 | In this video, we demonstrate the end-to-end user flow for planning a NovaSeq X run with BaseSpace® Run Planning and performing the run with data storage and automated analysis in Illumina® Connected Analytics (ICA).
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaInside the UK’s largest life sciences eventIllumina2024-01-29 | Illumina attended the ninth annual Festival of Genomics & Biodata in London. The annual event covered more topics than ever before such as diagnostics, drug discovery, AI, proteomics, single-cell & spatial analysis. As Illumina continues to fuel the revolution in genomics, we spoke with some attendees about what the future holds for the sector.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#genomics #FoG2024 #oncology #drug discovery #singlecellanalysis #spatialanalysisIllumina Oncology - CGP for clinical trial enrollmentIllumina2024-01-10 | Richard Schilsky, MD, explains how comprehensive genomic profiling is qualifying patients with cancer to participate in clinical trials that provide treatment options for them that they might not otherwise be able to access. Dr. Schilsky provides an overview of ASCO's TAPUR study and shares his perspective on a multi-omics approach for clinical trial design.
Richard Schilsky, MD, is the retired Chief Medical Officer and executive vice president of the American Society of Clinical Oncology (ASCO).
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaIllumina Oncology - Clinical utility of ctDNA testingIllumina2024-01-10 | Atocha Romero, PharmD, PhD, explains the value of liquid biopsy-based comprehensive genomic profiling. Dr. Romero provides an overview of the results of the NADIM II clinical trials and discusses ctDNA testing to monitor disease and guide treatment.
Atocha Romero, PharmD, PhD, is the director of the Liquid Biopsy Laboratory of the Medical Oncology Department at the Hospital Universitario Puerta de Hierro in Madrid, Spain.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaLearn How Zymo Research Advances Microbiome Research with the NextSeq 2000Illumina2023-12-19 | With the help of the NextSeq™ 2000, Zymo Research is delivering cost-effective and timely sequencing services to help scientist pursue more of the world’s biggest questions and keep their research moving forward. Keith Booher, Director of Research Services at Zymo Research, explains the diverse research his team supports including the fascinating world of microbiome research, the potential health and environmental benefits of understanding the microbiome, and how technological advancements are making the pursuit of this research possible.
For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#Illumina #NextSeq #BenchtopSequencingIllumina DNA Prep with Enrichment Dx-Achieve IVD compliant testing. Easily.Illumina2023-12-07 | Illumina DNA Prep with Enrichment Dx is an FDA-regulated and EU IVDR 2017/746-compliant solution for targeted sequencing in diagnostic applications. This Dx library preparation solution delivers validated performance when used with Illumina Dx sequencing instruments and Dx reagents.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaIllumina Oncology - Comprehensive genomic profiling utility in lung cancerIllumina2023-11-28 | Prof. Tony Mok discusses the benefits of biomarker testing for patients with lung cancer. He provides an overview of the value of genomic profiling in the first-line setting and highlights the importance of detecting resistance mutations for personalized treatments.
Tony Mok is a medical oncologist and professor at the Chinese University of Hong Kong.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaOICR & Princess Margaret: Changing the World with NovaSeq™ X PlusIllumina2023-11-28 | The Ontario Institute for Cancer Research (OICR) is working to better understand tumor biology and improve cancer care through the use of genomics. Their partner at Princess Margaret Cancer Centre, relies on OICR and whole-genome and transcriptome data to guide treatment and monitor disease progression as part of clinical trials.
At the core of this, is the sequencing performed on the NovaSeq™ X Plus. Learn how OICR is using the NovaSeq™ X Plus to accelerate projects, like those with Dr. Stephanie Lheureux at Princess Margaret. The economics, speed, and throughput are ultimately aiding both institutions in reaching their organizational goals and missions.
Video Chapters:
0:00 – The search for answers 0:35 - Meet Dr. Stephanie Lheureux 0:51 - Meet Dr. Bernard Lam 1:16 - Dr. Laszlo Radvanyi shares an overview of OICR 1:42 - How OICR and Princess Margaret collaborate 2:52 - Working with the NovaSeq™ X Plus 3:12 - The cancer genome and a brighter future for treatment
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#NovaSeqX #OICR #PrincessMargaretEl Valor del Perfil Genómico Integral (CGP) de ctDNA en Biopsia LíquidaIllumina2023-11-17 | El Perfil Genómico Integral (PGI) del ADN tumoral circulante (ctDNA) obtenido mediante biopsia líquida sanguínea proporciona resultados importantes para informar la selección de terapias posteriores.
En esta entrevista en video, la Dra. Atocha Romero, Directora del Laboratorio de Biopsia Líquida del Departamento de Oncología Médica del Hospital Universitario Puerta de Hierro en Madrid, España, comparte su perspectiva sobre el valor del PGI en ctDNA y explica cómo su equipo utilizó pruebas integrales de biomarcadores basadas en biopsias líquidas para pacientes con cáncer de pulmón en los ensayos clínicos NADIM II.
En particular, la entrevista aborda las siguientes preguntas:
¿Por qué utilizar la biopsia líquida? ¿Qué pacientes pueden ser seleccionados para la biopsia líquida? ¿Cuál es el valor del PGI del ctDNA? ¿Qué ventajas aporta este enfoque de prueba diagnóstica a los pacientes?
Vea el video para aprender más sobre cómo el perfil genómico integral del ctDNA obtenido mediante biopsia líquida puede mejorar el pronóstico y la gestión de los pacientes con cáncer, proporcionando información sobre la progresión tumoral y la respuesta a tratamientos basados en inmunoterapia.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaValue of Comprehensive Genomic Profiling (CGP) of ctDNA in Liquid biopsy – Dr. Atocha RomeroIllumina2023-11-08 | Comprehensive Genomic Profiling (CGP) of circulating tumor DNA (ctDNA) from blood liquid biopsy provides important results to inform subsequent therapy selection.
In this video interview, Dr. Atocha Romero, Director of the Liquid Biopsy Laboratory of the Medical Oncology Department at the Hospital Universitario Puerta de Hierro in Madrid, Spain, shares her perspective on the value of CGP on ctDNA and explains how her team used liquid biopsy-based comprehensive biomarker testing for lung cancer patients in NADIM II clinical trials.
In particular, the interview addresses these questions:
Why using liquid biopsy? Which patients can be selected for liquid biopsy? What is the value of CGP of ctDNA? What advantages does this diagnostic test approach bring to patients?
Watch video to learn more how comprehensive genomic profiling of ctDNA from liquid biopsy can improve the prognosis and management of cancer patients, by providing insights into tumor progression and response to immunotherapy-based treatments.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
Facebook: facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illuminaEnabling CGP from Liquid Biopsy with TruSight Oncology 500 ctDNA v2Illumina2023-11-03 | TruSight™ Oncology 500 ctDNA v2 is now available! Our next version comprehensive genomic profiling (CGP) from liquid biopsy (blood) offers higher analytical sensitivity from lower cfDNA input, faster turn-around time from purified nucleic acid to insights and a more streamlined workflow with automation options coming in 2024! Hear about these new features from Illumina development team and the excitement from early access users at Frederick National Laboratory.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#liquidbiopsy #precisionmedicine #CGP #NGS #oncologyEnabling CGP from Liquid Biopsy with TruSight Oncology 500 ctDNA v2Illumina2023-11-03 | TruSight™ Oncology 500 ctDNA v2 is now available! Our next version comprehensive genomic profiling (CGP) from liquid biopsy (blood) offers higher analytical sensitivity from lower cfDNA input, faster turn-around time from purified nucleic acid to insights and a more streamlined workflow with automation options coming in 2024! Hear more from early access users at Frederick National Laboratory.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
#liquidbiopsy #precisionmedicine #CGP #NGS #oncologyThe Power of Illumina ProactiveIllumina2023-10-30 | This video shows the value of connecting your Illumina instrument to Illumina Proactive, a transformative program that brings enhanced service, support, and lab management capabilities to your lab. The hosts explain how Illumina Proactive works, highlight examples of Illumina Proactive alerts preventing downtime, and demonstrate the enhanced features of MyIllumina when connected to Illumina Proactive.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMNextera Flex for Enrichment | A Faster, More Flexible WorkflowIllumina2023-10-23 | Do more with Nextera Flex for Enrichment. This fast, simple library prep and enrichment workflow from Illumina is compatible with custom, fixed, or exome panels from Illumina as well as third-party vendors and offers excellent performance, even with FFPE samples. Find out how to optimize your workflow with this flexible targeted sequencing solution.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 13 - add new processesIllumina2023-10-20 | In this user training video, you will learn how to add new processes in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 15 - Add new protocols and workflowsIllumina2023-10-20 | In this user training video, you will learn how to add new protocols and workflows in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 26 - Requeue Samples to an Earlier StepIllumina2023-10-20 | In this user training video, you will learn how to do requeue samples in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 24 - BioAnalyzer QC stepIllumina2023-10-20 | In this user training video, you will learn how the use BaseSpace™ Clarity LIMS to record a BioAnalyzer QC step.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 18 - Add user accountsIllumina2023-10-20 | In this user training video, you will learn how to add user accounts in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 19 - Add new container typeIllumina2023-10-20 | In this user training video, you will learn how to add new container type in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 20 - Configuring QC protocolsIllumina2023-10-20 | In this user training video, you will learn how to configuring QC protocols in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 21 - Request External Login for Clarity LIMS for LabLinkIllumina2023-10-20 | In this user training video, you will learn how to request a login for LabLink in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvMBaseSpace™ Clarity LIMS User Training Video 22 - Submitting Samples via LabLinkIllumina2023-10-20 | In this user training video, you will learn how to submit samples via LabLink in BaseSpace™ Clarity LIMS.
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.